Showing 1741-1750 of 5643 results for "".
- Updated Cataract PPP Raises Questions About Same-Day Bilateral Cataract Surgery and Office-based Cataract Surgeryhttps://modernod.com/news/updated-cataract-ppp-raises-questions-about-same-day-bilateral-cataract-surgery-and-office-based-cataract-surgery/2480467/The American Academy of Ophthalmology recognizes that immediate sequential bilateral cataract surgery (ISBCS) has the potential for some positive implications for patients. These include reduced out-of-pocket expense and fewer total visits to health care facilities. ISBCS has been adopted to a gr
- Altris AI Launches Altris Sync App Allowing AI to Directly Sync to OCT Deviceshttps://modernod.com/news/altris-ai-launches-altris-sync-app-allowing-ai-to-directly-sync-to-oct-devices-ai-now-connects-to-oct-devices-from-8-manufacturers-and-enables-analysis-of-historical-data/2482891/Altris AI announces the release of 'Altris Sync,' a secure application that syncs AI directly to OCT devices from 8 OCT manufacturers. The introduction of Altris Sync for automated upload of OCT files is desinged to remove the need for manual operations and bring AI de
- Lighthouse Guild and Bionic Sight Announce Partnership Designed to Expand Treatment Options for People Who Are Blindhttps://modernod.com/news/lighthouse-guild-and-bionic-sight-announce-partnership-designed-to-expand-treatment-options-for-people-who-are-blind/2481264/Lighthouse Guild and Bionic Sight announced that they are entering into a partnership designed to impoved the landscape of treatment for people who are blind. Bionic Sight’s technology focuses on restoring sight to patients with advanced stage blindness due to retinal de
- Brim Biotechnology and Ora Announce Partnership to Accelerate Development of Regenerative Peptide Therapy, BRM421, for Dry Eyehttps://modernod.com/news/brim-biotechnology-and-ora-inc-announce-new-partnership-to-accelerate-development-of-regenerative-peptide-therapy-brm421-for-dry-eye-syndrome/2480867/Brim Biotechnology announces it has entered into a new strategic partnership with Ora Inc. for the late-stage clinical development of lead drug candidate, BRM421, for dry eye syndrome (DES). Brim intends to initiate phase 3 clinical studies with Ora’s support later this year.
- Bausch Health Announces Vyzulta is Now Approved In Brazilhttps://modernod.com/news/bausch-health-announces-vyzulta-is-now-approved-in-brazil/2479084/Bausch Health Companies and Nicox announced that Vyzulta (latanoprostene bunod ophthalmic solution), 0.024%, has received regulatory approval from the Brazilian Health Regulatory Agency (ANVISA – Agência Nacional de Vigilância Sanitária). Vyzulta is indicated for the reduction of IOP in pa
- Researchers Take Step Closer to Developing AMD Eye Dropshttps://modernod.com/news/researchers-take-step-closer-to-developing-amd-eye-drops/2480007/Scientists at the University of Birmingham, UK, say they are one step closer to developing an eye drop that could revolutionize treatment for age-related macular degeneration (AMD), according to a university news release. Scientists led by biochemist Felicity de Cogan, PhD, from the Univer
- Study: Implandata’s Eyemate System Protects Glaucoma Patients–Even During Lockdownhttps://modernod.com/news/study-implandatas-eyemate-system-protects-glaucoma-patients-even-during-lockdown/2478767/Patients with glaucoma are at high risk of losing their eyesight if their disease progresses undetected and essential therapy adjustments are delayed. On the other hand, these typically elderly, vulnerable individuals are often hampered in seeing their doctor for office visits, particularly durin
- Valo Health Suspends Development of DR Drug Candidate After Phase 2 Study Resultshttps://modernod.com/news/valo-health-suspends-development-of-dr-drug-candidate-after-phase-2-study-results/2482594/Valo Health announced topline data from its phase 2 SPECTRA study of OPL-0401 in patients with diabetic retinopathy (DR). The study did not meet its primary or secondary endpoints based on the analysis in the prede&sh
- TP-03 Now Approved in China for the Treatment of Demodex Blepharitishttps://modernod.com/news/tp-03-now-approved-in-china-for-the-treatment-of-demodex-blepharitis/2486355/Key Takeaways TP-03 (XDEMVY) has been approved in China by the NMPA for treating Demodex blepharitis, marking a major expansion beyond th
- FDA Selects Dompé for National Priority Voucher Program to Accelerate Development of Novel Intranasal Therapyhttps://modernod.com/news/fda-selects-dompe-for-national-priority-voucher-program-to-accelerate-development-of-novel-intranasal-therapy/2484190/Dompé announced its selection by the FDA to participate in the Commissioner’s National Priority Voucher (CNPV) program. Through this designation, Dompé has been awarded a voucher granting a signific